Canada Trichomoniasis Drug Market Size & Outlook, 2026-2034


Canada Trichomoniasis Drug Market Insights

  • Reed Intelligence analysis indicates that the Canada Trichomoniasis Drug Market size, valued at USD 66.3 Million in 2025, is expected to expand to USD 117.96 Million by 2034.
  • The Canada market is forecasted to expand at a CAGR of 6.64% spanning 2026–2034.
  • Nitroimidazoles held the leading position among Drug Class segments in 2025, based on market size.
  • Combination Therapies is projected to post the fastest growth rate, sustaining its position as the most attractive Drug Class segment during the forecast horizon.

Other Key Findings


  • In 2025, Canada represented 8.09% of the overall global Trichomoniasis Drug Market size.
  • United States is projected to lead the global Trichomoniasis Drug Market size by 2034.
  • Across North America, United States is anticipated to hold the dominant position in market size by 2034.
  • Canada is forecasted to expand at the fastest pace in North America, attaining USD 118.25 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 66.3 Million
Market Size In 2034 USD 117.96 Million
Largest segment Nitroimidazoles
Units Revenue in USD Million
CAGR 6.64% (2026-2034)
Segmnetation Covered
Drug Class
  1. Nitroimidazoles
  2. Combination Therapies
  3. Others
Route of Administration
  1. Oral
  2. Topical
  3. Injectable
Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
Patient Demographics
  1. Adult Women
  2. Adult Men
  3. Adolescents
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports